Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/41150
SINGLE-DOSE RIFAMPICIN CHEMOPROPHYLAXIS PROTECTS THOSE WHO NEED IT LEAST AND IS NOT A COST-EFFECTIVE INTERVENTION
Rifampina
Análise custo-benefício
Serviços Preventivos de Saúde
Mycobacterium leprae
Doenças Negligenciadas
Doenças Transmissíveis
Affilliation
London School of Hygiene and Tropical Medicine. London, United Kingdom.
Damien Foundation of India Trust. Chennai, India.
Postgraduate Institute of Medical Education and Research. Department of Dermatology, STD and Leprosy. Chandigarh, India.
Universidade de Brasília. Faculdade de Medicina. Núcleo de Medicina Tropical. Brasília, DF, Brasil / Fundação Oswaldo Cruz. Brasília, DF, Brasil.
Damien Foundation of India Trust. Chennai, India.
Postgraduate Institute of Medical Education and Research. Department of Dermatology, STD and Leprosy. Chandigarh, India.
Universidade de Brasília. Faculdade de Medicina. Núcleo de Medicina Tropical. Brasília, DF, Brasil / Fundação Oswaldo Cruz. Brasília, DF, Brasil.
Abstract
Single-dose rifampicin (SDR) treatment being offered to household contacts of new leprosy patients is being practiced by the Indian National Leprosy Programme since November 2017. We are concerned, because this is not an effective method for preventing multibacillary (MB) leprosy. It does not protect against the development of MB leprosy and does not protect immediate household contacts for a reasonable period of time. There are serious ethical problems related to identifying the contacts of patients with leprosy, it is not cost effective for household contacts, and there is a possibility of the widespread use of SDR promoting the development of rifampicin resistance genes in Mycobacterium leprae.
DeCS
HanseníaseRifampina
Análise custo-benefício
Serviços Preventivos de Saúde
Mycobacterium leprae
Doenças Negligenciadas
Doenças Transmissíveis
Share